Veradigm Analyst Ratings
Veradigm Analyst Ratings
Veradigm 分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | -6.27% | Stephens & Co. | → $13 | Reiterates | Equal-Weight → Equal-Weight |
| 07/06/2023 | — | Argus Research | Downgrades | Buy → Hold | |
| 04/12/2023 | -6.27% | Stephens & Co. | → $13 | Initiates Coverage On | → Equal-Weight |
| 02/01/2023 | 33.38% | Piper Sandler | $17 → $18.5 | Downgrades | Overweight → Neutral |
| 12/07/2022 | 87.45% | Argus Research | → $26 | Upgrades | Hold → Buy |
| 11/18/2022 | 44.2% | JP Morgan | $19 → $20 | Maintains | Underweight |
| 11/09/2022 | 65.83% | Goldman Sachs | $22 → $23 | Upgrades | Neutral → Buy |
| 09/16/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 07/12/2022 | 51.41% | Goldman Sachs | → $21 | Initiates Coverage On | → Neutral |
| 06/10/2022 | 22.57% | Piper Sandler | $19 → $17 | Maintains | Neutral |
| 05/06/2022 | 36.99% | Piper Sandler | $22 → $19 | Maintains | Neutral |
| 03/18/2022 | 58.62% | Piper Sandler | $19 → $22 | Maintains | Neutral |
| 03/04/2022 | 87.45% | Deutsche Bank | $20 → $26 | Upgrades | Hold → Buy |
| 03/03/2022 | 73.04% | SVB Leerink | $22 → $24 | Maintains | Outperform |
| 01/25/2022 | 58.62% | SVB Leerink | $19 → $22 | Upgrades | Market Perform → Outperform |
| 11/23/2021 | 44.2% | Deutsche Bank | $18 → $20 | Maintains | Hold |
| 08/06/2021 | 36.99% | RBC Capital | $17 → $19 | Maintains | Outperform |
| 08/06/2021 | 36.99% | SVB Leerink | $17 → $19 | Maintains | Market Perform |
| 05/26/2021 | 22.57% | SVB Leerink | $16 → $17 | Maintains | Market Perform |
| 04/30/2021 | 15.36% | SVB Leerink | $15 → $16 | Maintains | Market Perform |
| 04/30/2021 | 29.78% | Canaccord Genuity | $17 → $18 | Maintains | Buy |
| 03/02/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 02/26/2021 | 8.15% | SVB Leerink | $16 → $15 | Maintains | Market Perform |
| 11/25/2020 | 18.96% | B of A Securities | $14 → $16.5 | Maintains | Buy |
| 10/19/2020 | -6.27% | Baird | → $13 | Downgrades | Outperform → Neutral |
| 10/14/2020 | -6.27% | Cantor Fitzgerald | $9 → $13 | Maintains | Neutral |
| 10/14/2020 | -6.27% | SVB Leerink | $10 → $13 | Maintains | Market Perform |
| 08/24/2020 | -35.11% | JP Morgan | $8 → $9 | Maintains | Neutral |
| 08/11/2020 | -42.32% | Morgan Stanley | $6 → $8 | Maintains | Underweight |
| 08/03/2020 | -27.9% | RBC Capital | $8 → $10 | Maintains | Outperform |
| 07/31/2020 | -35.11% | Cantor Fitzgerald | $6 → $9 | Maintains | Neutral |
| 07/31/2020 | -27.9% | SVB Leerink | $6 → $10 | Maintains | Market Perform |
| 07/21/2020 | -60.35% | Goldman Sachs | $6.5 → $5.5 | Downgrades | Neutral → Sell |
| 05/13/2020 | -56.74% | Morgan Stanley | $5 → $6 | Maintains | Underweight |
| 05/13/2020 | -49.53% | SunTrust Robinson Humphrey | $6 → $7 | Maintains | Hold |
| 05/08/2020 | -56.74% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 05/08/2020 | -56.74% | Cantor Fitzgerald | $8 → $6 | Reiterates | → Neutral |
| 04/22/2020 | -49.53% | Jefferies | $10.5 → $7 | Downgrades | Buy → Hold |
| 04/21/2020 | -42.32% | RBC Capital | → $8 | Initiates Coverage On | → Outperform |
| 03/05/2020 | -35.11% | SunTrust Robinson Humphrey | $11 → $9 | Maintains | Hold |
| 03/04/2020 | -20.69% | Deutsche Bank | $12 → $11 | Maintains | Hold |
| 03/03/2020 | -56.74% | CFRA | $9 → $6 | Maintains | Strong Sell |
| 03/03/2020 | -27.9% | Baird | $13 → $10 | Maintains | Outperform |
| 03/03/2020 | -42.32% | Cantor Fitzgerald | $11 → $8 | Reiterates | → Neutral |
| 11/26/2019 | -17.09% | UBS | → $11.5 | Initiates Coverage On | → Neutral |
| 09/26/2019 | -20.69% | Deutsche Bank | → $11 | Initiates Coverage On | → Hold |
| 02/25/2019 | -13.48% | Citigroup | $14 → $12 | Downgrades | Buy → Neutral |
| 02/22/2019 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 02/22/2019 | -13.48% | Citigroup | $14 → $12 | Downgrades | Buy → Neutral |
| 01/18/2019 | — | Keybanc | Upgrades | Sector Weight → Overweight | |
| 11/14/2018 | — | Argus Research | Downgrades | Buy → Hold | |
| 11/02/2018 | 8.15% | B of A Securities | $16.5 → $15 | Maintains | Buy |
| 11/02/2018 | 0.94% | Baird | $16 → $14 | Maintains | Outperform |
| 11/02/2018 | 22.57% | Citigroup | $19 → $17 | Maintains | Buy |
| 11/02/2018 | -13.48% | JP Morgan | $16 → $12 | Downgrades | Overweight → Neutral |
| 11/02/2018 | -13.48% | Cantor Fitzgerald | → $12 | Downgrades | Overweight → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月10日 | -6.27% | 斯蒂芬斯公司 | →$13 | 重申 | 等重→等重 |
| 07/06/2023 | - | Argus研究 | 評級下調 | 購買→Hold | |
| 04/12/2023 | -6.27% | 斯蒂芬斯公司 | →$13 | 開始承保 | →等重 |
| 02/01/2023 | 33.38% | 派珀·桑德勒 | $17→$18.5 | 評級下調 | 超重→中性 |
| 12/07/2022 | 87.45% | Argus研究 | →$26 | 升級 | 持有→購買 |
| 2022年11月18日 | 44.2% | 摩根大通 | $19→$20 | 維護 | 體重不足 |
| 11/09/2022 | 65.83% | 高盛 | $22→$23 | 升級 | 中性→購買 |
| 09/16/2022 | - | KeyBanc | 開始承保 | →行業權重 | |
| 07/12/2022 | 51.41% | 高盛 | →$21 | 開始承保 | →中性 |
| 2022/10/06 | 22.57% | 派珀·桑德勒 | $19→$17 | 維護 | 中性 |
| 05/06/2022 | 36.99% | 派珀·桑德勒 | $22→$19 | 維護 | 中性 |
| 03/18/2022 | 58.62% | 派珀·桑德勒 | $19→$22 | 維護 | 中性 |
| 03/04/2022 | 87.45% | 德意志銀行 | $20→$26 | 升級 | 持有→購買 |
| 03/03/2022 | 73.04% | SVB Leerink | $22→$24 | 維護 | 跑贏大盤 |
| 01/25/2022 | 58.62% | SVB Leerink | $19→$22 | 升級 | 市場表現優於→ |
| 2021年11月23日 | 44.2% | 德意志銀行 | $18→$20 | 維護 | 保持 |
| 08/06/2021 | 36.99% | 加拿大皇家銀行資本 | $17→$19 | 維護 | 跑贏大盤 |
| 08/06/2021 | 36.99% | SVB Leerink | $17→$19 | 維護 | 市場表現 |
| 2021/05/26 | 22.57% | SVB Leerink | $16→$17 | 維護 | 市場表現 |
| 04/30/2021 | 15.36% | SVB Leerink | $15→$16 | 維護 | 市場表現 |
| 04/30/2021 | 29.78% | 卡納科特·格納奇 | $17→$18 | 維護 | 買 |
| 03/02/2021 | - | Argus研究 | 評級下調 | 購買→Hold | |
| 02/26/2021 | 8.15% | SVB Leerink | $16→$15 | 維護 | 市場表現 |
| 11/25/2020 | 18.96% | B of A證券 | $14→$16.5 | 維護 | 買 |
| 10/19/2020 | -6.27% | 貝爾德 | →$13 | 評級下調 | 跑贏→中性 |
| 10/14/2020 | -6.27% | 康託·菲茨傑拉德 | $9→$13 | 維護 | 中性 |
| 10/14/2020 | -6.27% | SVB Leerink | $10→$13 | 維護 | 市場表現 |
| 08/24/2020 | -35.11% | 摩根大通 | $8→$9 | 維護 | 中性 |
| 2020年08月11日 | -42.32% | 摩根士丹利 | $6→$8 | 維護 | 體重不足 |
| 08/03/2020 | -27.9% | 加拿大皇家銀行資本 | $8→$10 | 維護 | 跑贏大盤 |
| 07/31/2020 | -35.11% | 康託·菲茨傑拉德 | $6→$9 | 維護 | 中性 |
| 07/31/2020 | -27.9% | SVB Leerink | $6→$10 | 維護 | 市場表現 |
| 07/21/2020 | -60.35% | 高盛 | $6.5→$5.5 | 評級下調 | 中性→銷售 |
| 2020/05/13 | -56.74% | 摩根士丹利 | $5→$6 | 維護 | 體重不足 |
| 2020/05/13 | -49.53% | SunTrust Robinson Humphrey | $6→$7 | 維護 | 保持 |
| 05/08/2020 | -56.74% | SVB Leerink | $8→$6 | 維護 | 市場表現 |
| 05/08/2020 | -56.74% | 康託·菲茨傑拉德 | $8→$6 | 重申 | →中性 |
| 04/22/2020 | -49.53% | 傑富瑞 | $10.5→$7 | 評級下調 | 購買→Hold |
| 04/21/2020 | -42.32% | 加拿大皇家銀行資本 | →$8 | 開始承保 | →跑贏大盤 |
| 03/05/2020 | -35.11% | SunTrust Robinson Humphrey | $11→$9 | 維護 | 保持 |
| 03/04/2020 | -20.69% | 德意志銀行 | $12→$11 | 維護 | 保持 |
| 03/03/2020 | -56.74% | CFRA | $9→$6 | 維護 | 強勁的銷售 |
| 03/03/2020 | -27.9% | 貝爾德 | $13→$10 | 維護 | 跑贏大盤 |
| 03/03/2020 | -42.32% | 康託·菲茨傑拉德 | $11→$8 | 重申 | →中性 |
| 2019年11月26日 | -17.09% | 瑞銀集團 | →$11.5 | 開始承保 | →中性 |
| 2019年09月26日 | -20.69% | 德意志銀行 | →$11 | 開始承保 | →保留 |
| 2019年02月25日 | -13.48% | 花旗集團 | $14→$12 | 評級下調 | 購買→中性 |
| 2019年02月22日 | - | KeyBanc | 評級下調 | 增持→板塊權重 | |
| 2019年02月22日 | -13.48% | 花旗集團 | $14→$12 | 評級下調 | 購買→中性 |
| 2019年01月18日 | - | KeyBanc | 升級 | 行業權重→超配 | |
| 2018年11月14日 | - | Argus研究 | 評級下調 | 購買→Hold | |
| 11/02/2018 | 8.15% | B of A證券 | $16.5→$15 | 維護 | 買 |
| 11/02/2018 | 0.94% | 貝爾德 | $16→$14 | 維護 | 跑贏大盤 |
| 11/02/2018 | 22.57% | 花旗集團 | $19→$17 | 維護 | 買 |
| 11/02/2018 | -13.48% | 摩根大通 | $16→$12 | 評級下調 | 超重→中性 |
| 11/02/2018 | -13.48% | 康託·菲茨傑拉德 | →$12 | 評級下調 | 超重→中性 |
What is the target price for Veradigm (MDRX)?
Veradigm的目標價是多少？
The latest price target for Veradigm (NASDAQ: MDRX) was reported by Stephens & Co. on October 10, 2023. The analyst firm set a price target for $13.00 expecting MDRX to fall to within 12 months (a possible -6.27% downside). 7 analyst firms have reported ratings in the last year.
斯蒂芬斯公司於2023年10月10日報道了Veradigm(納斯達克代碼：MDRX)的最新目標價。這家分析公司將MDRX的目標價設定為13.00美元，預計MDRX將在12個月內下跌(可能下跌6.27%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Veradigm (MDRX)?
最新的分析師對Veradigm的評級是多少？
The latest analyst rating for Veradigm (NASDAQ: MDRX) was provided by Stephens & Co., and Veradigm reiterated their equal-weight rating.
斯蒂芬斯公司提供了對Veradigm(納斯達克代碼：MDRX)的最新分析師評級，Veradigm重申了它們的同等權重評級。
When is the next analyst rating going to be posted or updated for Veradigm (MDRX)?
Veradigm(MDRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veradigm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veradigm was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Veradigm的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Veradigm的上一次評級是在2023年10月10日提交的，所以你應該預計下一次評級將在2024年10月10日左右的某個時候公佈。
Is the Analyst Rating Veradigm (MDRX) correct?
分析師評級Veradigm(MDRX)正確嗎？
While ratings are subjective and will change, the latest Veradigm (MDRX) rating was a reiterated with a price target of $0.00 to $13.00. The current price Veradigm (MDRX) is trading at is $13.87, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Veradigm(MDRX)評級被重申，目標價在0.00美元至13.00美元之間。目前Veradigm的交易價格為13.87美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。